Spyre Therapeutics, Inc. SYRE Enterprise value

Enterprise value at other companies

Bristol-Myers SquibbBMY

$152.27B+14.9%

Eli LillyLLY

$1.12T+51.8%

PfizerPFE

$222.4B+9.2%

Johnson & JohnsonJNJ

$639.97B+60.7%

Merck & Co.MRK

$367.21B+59.3%

AbbVieABBV

$460.96B+24.7%

FAQ

What is Spyre Therapeutics, Inc.'s enterprise value?

Spyre Therapeutics, Inc. (SYRE) reported enterprise value of -$189.23M in Q2 2023.

How has Spyre Therapeutics, Inc.'s enterprise value changed year-over-year?

Spyre Therapeutics, Inc.'s enterprise value decreased by 1369.0% year-over-year, from $14.91M to -$189.23M.

What is the long-term trend for Spyre Therapeutics, Inc.'s enterprise value?

Over 2 years (2020 to 2022), Spyre Therapeutics, Inc.'s enterprise value has grown at a -91.6% compound annual growth rate (CAGR), from $335.46M to -$2.36M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.